NLRP3 and ovarian cancer: Ori forms a covalent bond with cysteine 279 in the NACHT domain of NLRP3, thereby disrupting the NLRP3-NEK7 interaction and inhibiting inflammasome assembly and activation—a mechanism that has been confirmed in ovarian cancer (146).